Pss33 Development of a New Measure for Assessing Healthrelated Quality of Life in Patientes With Psoariasis: ‘Pso-Life’

Sánchez-Carazo, JL; Daudén, E.; Herrera, Enrique; Toribio, Jaime; Puig, Lluís; Sabater, FJ; Perulero, N; Badia, X

doi:10.1016/s1098-3015(10)75270-0

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Rasch analysis was used to exclude those items with INFIT or OUTFIT > 1.30 and <0.70 and those which were redundant with other items. This final questionnaire, with a total of 20 items has good preliminary internal consistency (Cronbach’s alpha = 0.94) [ 18 ].…”

Section: Methodsmentioning

confidence: 99%

“…In an attempt to overcome some of these drawbacks to measurement of HRQOL of patients with psoriasis in Spain, the PSO-LIFE (Psoriasis Quality of Life) instrument was developed [ 18 ]. It is a 20 item instrument covering aspects ranging from symptoms to the impact on emotional well-being, relationships, and activities and leisure, which had not been validated to date.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire

Daudén

Herrera

Puig

et al. 2012

Health Qual Life Outcomes

View full text Add to dashboard Cite

BackgroundSeveral questionnaires have been used to measure health related quality of life (HRQoL) in patients with psoriasis, few have been adapted for use in Spain; none of them was developed specifically for the Spanish population. The purpose of the study was to validate and assess the sensitivity to change of a new questionnaire to measure HRQOL in patients with psoriasis (PSO-LIFE).MethodsObservational, prospective, multicenter study performed in centers around Spain. Patients with active or inactive psoriasis completed the PSO-LIFE together with other Dermatology Quality of Life Index (DLQI) and Psoriasis Disability Index (PDI). A control group of patients with urticaria or atopic dermatitis was also included. Internal consistency and test-retest reliability of the PSO-LIFE were assessed by calculating Cronbach’s alpha and Intraclass Correlation Coefficient (ICC). Validity was assessed by examining factorial structure, the capacity to discriminate between groups, and correlations with other measures. Sensitivity to change was measured using effect sizes.ResultsThe final sample included for analysis consisted of 304 patients and 56 controls. Mean (SD) age of psoriasis patients was 45.3 (14.5) years compared to 38.8 (14) years for controls (p < 0.01). Cronbach’s alpha for the PSO-LIFE was 0.95 and test-retest reliability using the ICC was 0.98. Factor analysis showed the questionnaire to be unidimensional. Mean (SD) PSO-LIFE scores differed between patients with psoriasis and controls (64.9 [22.5] vs 69.4 [17.3]; p < 0.05), between those with active and inactive disease (57.4 [20.4] vs 76.4 [20.6]; p < 0.01), and between those with visible and non-visible lesions (63.0 [21.9] vs. 74.8 [23.9]; p < 0.01). The correlation between PSO-LIFE and PASI scores was moderate (r = −0.43) while correlations with DLQI and PDI dimensions ranged from moderate to high (between 0.4 and 0.8). Effect size on the PSO-LIFE in patients reporting ‘much improved’ health status at study completion was 1.01 (large effect size).ConclusionsThe present results provide substantial support for the reliability, validity, and responsiveness of the PSO-LIFE questionnaire in the population for which it was designed.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire

Daudén

Herrera

Puig

et al. 2012

Health Qual Life Outcomes

View full text Add to dashboard Cite

show abstract

“…Additionally, the number of patients active in answering the questionnaires was also obtained (a patient is considered active when the percentage of questionnaires answered is higher or equal to 50%). The selected questionnaires were: Psoriasis Quality of Life (PSOLIFE) [ 27 ]: PSOLIFE is a psoriasis quality of life questionnaire consisting of 20-item responses with a range from 20 to 100 points. Higher values of PSOLIFE score mean a better quality of life related to health (or less impact on the quality of life) [ 28 ]; Dermatology Life Quality Index (DLQI): DLQI is a dermatological quality of life questionnaire consisting of 10-item responses with a range from 0 to 30 points.…”

Section: Materials and Methodsmentioning

confidence: 99%

“…Psoriasis Quality of Life (PSOLIFE) [ 27 ]: PSOLIFE is a psoriasis quality of life questionnaire consisting of 20-item responses with a range from 20 to 100 points. Higher values of PSOLIFE score mean a better quality of life related to health (or less impact on the quality of life) [ 28 ];…”

Section: Materials and Methodsmentioning

confidence: 99%

When Virtual Assistants Meet Teledermatology: Validation of a Virtual Assistant to Improve the Quality of Life of Psoriatic Patients

Roca

Almenara-Blasco

Gilaberte

et al. 2022

IJERPH

View full text Add to dashboard Cite

Teledermatology has given dermatologists a tool to track patients’ responses to therapy using images. Virtual assistants, the programs that interact with users through text or voice messages, could be used in teledermatology to enhance the interaction of the tool with the patients and healthcare professionals and the overall impact of the medication and quality of life of patients. As such, this work aimed to investigate the effectiveness of using a virtual assistant for teledermatology and its impact on the quality of life. We conducted surveys with the participants and measured the usability of the system with the System Usability Scale (SUS). A total of 34 participants (30 patients diagnosed with moderate-severe psoriasis and 4 healthcare professionals) were included in the study. The measurement of the improvement of quality of life was done by analyzing Psoriasis Quality of Life (PSOLIFE) and Dermatology Life Quality Index (DLQI) questionnaires. The results showed that, on average, the quality of life improved (from 63.8 to 64.8 for PSOLIFE (with a p-value of 0.66 and an effect size of 0.06) and 4.4 to 2.8 for DLQI (with a p-value of 0.04 and an effect size of 0.31)). Patients also used the virtual assistant to do 52 medical consultations. Moreover, the usability is above average, with a SUS score of 70.1. As supported by MMAS-8 results, adherence also improved slightly. Our work demonstrates the improvement of the quality of life with the use of a virtual assistant in teledermatology, which could be attributed to the sense of security or peace of mind the patients get as they can contact their dermatologists directly within the virtual assistant-integrated system.

show abstract

Pss33 Development of a New Measure for Assessing Healthrelated Quality of Life in Patientes With Psoariasis: ‘Pso-Life’

Cited by 2 publications

References 0 publications

Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire

Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire

When Virtual Assistants Meet Teledermatology: Validation of a Virtual Assistant to Improve the Quality of Life of Psoriatic Patients

Contact Info

Product

Resources

About